BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hosseinzadeh A, Merikhian P, Naseri N, Eisavand MR, Farahmand L. MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy. Cancer Cell Int 2022;22. [DOI: 10.1186/s12935-022-02523-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen H, Zhou L, Li J, Hu K. ALKBH family members as novel biomarkers and prognostic factors in human breast cancer. Aging (Albany NY) 2022;14. [PMID: 35980268 DOI: 10.18632/aging.204231] [Reference Citation Analysis]
2 Tian Z, Yang Y, Wu H, Chen Y, Jia H, Zhu L, He R, Jin Y, Zhou B, Ge C, Sun Y, Yang Y. The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers. Heliyon 2022;8:e10410. [DOI: 10.1016/j.heliyon.2022.e10410] [Reference Citation Analysis]
3 Polewko-klim A, Zhu S, Wu W, Xie Y, Cai N, Zhang K, Zhu Z, Qing T, Yuan Z, Xu K, Zhang T, Lu M, Ye W, Chen X, Suo C, Rudnicki WR. Identification of Candidate Therapeutic Genes for More Precise Treatment of Esophageal Squamous Cell Carcinoma and Adenocarcinoma. Front Genet 2022;13:844542. [DOI: 10.3389/fgene.2022.844542] [Reference Citation Analysis]